Talya Shragai

Dr. Talya Shragai

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in NeoBiota
Verified
Journal Article
Open access
PDF file
AGAndrea Gloria-Soria
Andrea Gloria-Soria
TSTalya Shragai
Talya Shragai
ACAlexander Ciota
Alexander Ciota
TDTodd B. Duval
Todd B. Duval
BABarry Alto
Barry Alto
PAPhilip M. Armstrong
Philip M. Armstrong
The Asian tiger mosquito (Aedes albopictus) arrived in the USA in the 1980’s and rapidly spread throughout eastern USA within a decade. The predicted northern edge of its overwintering distribution on the East Coast of the USA roughly falls across New York, Connecticut, and Massachusetts, where the species has been recorded as early as 2000. It is unclear whether Ae. albopictus populations have become established and survive the cold winters in these areas or are recolonized every year. We genotyped and analyzed populations of Ae. albopictus from the northeast USA using 15 microsatellite markers and compared them with other populations across the country and to representatives of the major global genetic clades to investigate their connectivity and stability. Founder effects or bottlenecks were rare at the northern range of the Ae. albopictus distribution in the northeastern USA, with populations displaying high levels of genetic diversity and connectivity along the East Coast. There is no evidence of population turnover in Connecticut during the course of three consecutive years, with consistent genetic structure throughout this period. Overall, these results support the presence of established populations of Ae. albopictus in New York, Connecticut, and Massachusetts, successfully overwintering and migrating in large numbers. Given the stability and interconnectedness of these populations, Ae. albopictus has the potential to continue to proliferate and expand its range northward under mean warming conditions of climate change. Efforts to control Ae. albopictus in these areas should thus focus on vector suppression rather than eradication strategies, as local populations have become firmly established and are expected to reemerge every summer.

4 June 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
TSTalya Shragai
Talya Shragai
ASAimee Summers
Aimee Summers
OOOlu Olushayo
Olu Olushayo
JRJohn Rumunu
John Rumunu
VMValerie Mize
Valerie Mize
SBSudhir Bunga
Sudhir Bunga
This report describes the effect of policy, funding, and strategy changes on COVID-19 surveillance in the South Sudan.

17 January 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
TSTalya Shragai
Talya Shragai
OAOluwasegun Joel Adegoke
Oluwasegun Joel Adegoke
HIHadley Ikwe
Hadley Ikwe
TSTemilade Sorungbe
Temilade Sorungbe
AHAminu Haruna
Aminu Haruna
OBOmotayo Bolu
Omotayo Bolu
Nigeria began administering COVID-19 vaccines on 5 March 2021 and is working towards the WHO’s African regional goal to fully vaccinate 70% of their eligible population by December 2022. Nigeria’s COVID-19 vaccination information system includes a surveillance system for COVID-19 adverse events following immunisation (AEFI), but as of April 2021, AEFI data were being collected and managed by multiple groups and lacked routine analysis and use for action. To fill this gap in COVID-19 vaccine safety monitoring, between April 2021 and June 2022, the US Centers for Disease Control and Prevention, in collaboration with other implementing partners led by the Institute of Human Virology Nigeria, supported the Government of Nigeria to triangulate existing COVID-19 AEFI data. This paper describes the process of implementing published draft guidelines for data triangulation for COVID-19 AEFI data in Nigeria. Here, we focus on the process of implementing data triangulation rather than analysing the results and impacts of triangulation. Work began by mapping the flow of COVID-19 AEFI data, engaging stakeholders and building a data management system to intake and store all shared data. These datasets were used to create an online dashboard with key indicators selected based on existing WHO guidelines and national guidance. The dashboard went through an iterative review before dissemination to stakeholders. This case study highlights a successful example of implementing data triangulation for rapid use of AEFI data for decision-making and emphasises the importance of stakeholder engagement and strong data governance structures to make data triangulation successful.

1 June 2022 in Emerging Infectious Diseases
Verified
Journal Article
Open access
TSTalya Shragai
Talya Shragai
LTLeisel Talley
Leisel Talley
ASAimee Summers
Aimee Summers
HBHannah Behringer
Hannah Behringer
MWMaria Wrabel
Maria Wrabel
ELEva Leidman
Eva Leidman
Outcomes after Acute Malnutrition Program Adaptations

3 July 2021 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TSTalya Shragai
Talya Shragai
SSSarah E Smith-Jeffcoat
Sarah E Smith-Jeffcoat
MKMitsuki Koh
Mitsuki Koh
MSMarcos C Schechter
Marcos C Schechter
PRPaulina A Rebolledo
Paulina A Rebolledo
HTHong Tao
Hong Tao
Background: The natural history and clinical progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can be better understood using combined serological and reverse-transcription polymerase chain reaction (RT-PCR) testing. Methods: Nasopharyngeal swabs and serum were collected at a single time-point from patients at an urban, public hospital during August–November 2020 and tested for SARS-CoV-2 using RT-PCR, viral culture, and anti-spike pan-immunoglobulin antibody testing. Participant demographics and symptoms were collected through interview. The χ 2 and Fisher exact tests were used to identify associations between RT-PCR and serology results with presence of viable virus and frequency of symptoms. Results: Among 592 participants, 129 (21.8%) had evidence of SARS-CoV-2 infection by RT-PCR or serology. Presence of SARS-CoV-2 antibodies was strongly associated with lack of viable virus (P = .016). COVID-19 symptom frequency was similar for patients testing RT-PCR positive/seronegative and patients testing RT-PCR positive/seropositive. Patients testing RT-PCR positive/seronegative reported headaches, fatigue, diarrhea, and vomiting at rates not statistically significantly different from those testing RT-PCR negative/seropositive. Conclusions: While patients testing SARS-CoV-2 seropositive were unlikely to test positive for viable virus and were therefore at low risk for forward transmission, coronavirus disease 2019 (COVID-19) symptoms were common. Paired SARS-CoV-2 RT-PCR and antibody testing provides more nuanced understanding of patients’ COVID-19 status.

30 January 2024 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
TSTalya Shragai
Talya Shragai
ABArish Bukhari
Arish Bukhari
AAAjiri Okpure Atagbaza
Ajiri Okpure Atagbaza
DODaniel Rasheed Oyaole
Daniel Rasheed Oyaole
RSRonak Shah
Ronak Shah
BIBenido Impouma
Benido Impouma
This manuscript describes the process and impact of strengthening the WHO Regional Office for Africa (WHO AFRO)’s COVID-19 vaccination information system. This system plays a critical role in tracking vaccination coverage, guiding resource allocation and supporting vaccination campaign roll-out for countries in the African region. Recognising existing data management issues, including complex reporting prone to human error, compromised data quality and underutilisation of collected data, WHO AFRO introduced significant system improvements during the COVID-19 pandemic. These improvements include shifting from an Excel-based to an online Azure-based data collection system, automating data processing and validation, and expansion of collected data. These changes have led to improvements in data quality and quantity including a decrease in data non-validity, missingness, and record duplication, and expansion of data collection forms to include a greater number of data fields, offering a more comprehensive understanding of vaccination efforts. Finally, the creation of accessible information products—including an interactive public dashboard, a weekly data pack and a public monthly bulletin—has improved data use and reach to relevant partners. These resources provide crucial insights into the region’s vaccination progress at national and subnational levels, thereby enabling data-driven decision-making to improve programme performance. Overall, the strengthening of the WHO AFRO COVID-19 vaccination information system can serve as a model for similar efforts in other WHO regions and contexts. The impact of system strengthening on data quality demonstrated here underscores the vital role of robust data collection, capacity building and management systems in achieving high-quality data on vaccine distribution and coverage. Continued investment in information systems is essential for effective and equitable public health efforts.